Cited by 1,294Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 207 of the 208 references it cites were found in a registry or an index.

Translational biology of osteosarcoma

Kansara, Maya, Teng, Michele W., Smyth, Mark J., Thomas, David M.·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.

Integrity signals

Registry

Crossref · 10.1038/nrc3838

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citation
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,072
WHO classification of tumours of soft tissue and bone
Fletcher, C. D. �. (2013) · Cited by 2,874
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Alternative lengthening of telomeres: models, mechanisms and implications
Cesare, A. J., & Reddel, R. R. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2763 · Cited by 1,107
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,083
Requirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A. A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 906
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 901
Self-citation
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H. I., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 719
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717
Isolation and Characterization of MC3T3-E1 Preosteoblast Subclones with Distinct In Vitro and In Vivo Differentiation/Mineralization Potential
Wang, D., Christensen, K., Chawla, K., Xiao, G., Krebsbach, P. H., & Franceschi, R. T. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.6.893 · Cited by 666
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 632
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint
Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 601
Cell biology of the osteoclast
Roodman, G. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00061-2 · Cited by 583
Osteoimmunology: Interactions of the Bone and Immune System
Lorenzo, J., Horowitz, M. C., & Choi, Y. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0038 · Cited by 576
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. M. M. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 482
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 481
The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).
COLEY, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 425
Bloom’s Syndrome
GERMAN, J. L. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30101-3 · Cited by 423
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.
Hansen, M. F., Koufos, A., Gallie, B. L., Phillips, R. A., Fodstad, Ø., Brögger, A., Gedde‐Dahl, T., & Cavenee, W. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6216 · Cited by 414
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21335 · Cited by 389
Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose
Vahle, J. L., Long, G. G., Sandusky, G. E., Westmore, M. S., Ma, Y. L., & Sato, M. (2004) · Toxicologic Pathology · doi:10.1080/01926230490462138 · Cited by 376
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Association Between Osteosarcoma and Deleterious Mutations in the RECQL4 Gene in Rothmund-Thomson Syndrome
Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338
Bloom's syndrome. XX. The first 100 cancers
GERMAN, J. L. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00336-6 · Cited by 318
Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma
Gorlick, R. G., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 301
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 296
Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., & Sakai, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7786 · Cited by 289
Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Cultures of Human Bone Cells
Gronthos, S., Zannettino, A. C. W., Graves, S. E., Ohta, S., Hay, S. J., & Simmons, P. J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.47 · Cited by 281
Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions
Quinn, J. M. W., Itoh, K., Udagawa, N., Häusler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1787 · Cited by 278
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P., Simmons, P. J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37175 · Cited by 273
Self-citation
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D’Amato, G. Z., Blay, J., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 247
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review
Lauper, J. M., Krause, A. J., Vaughan, T. L., & Monnat, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059709 · Cited by 234
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Luduec, J.-B. L., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S. I., Heller, G., Dupont, B., Cheung, N. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 229
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide
MacEwen, E. G., Kurzman, I. D., ROSENTHAL, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 227
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma
Toguchida, J., Ishizaki, K., Sasaki, M. S., Nakamura, Y., Ikenaga, M., Kato, M. V., Sugimot, M., Kotoura, Y., & Yamamuro, T. (1989) · Nature · doi:10.1038/338156a0 · Cited by 215
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L. J., Wang, Z., Gastier, J. M., Gorlick, R. G., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 200
Self-citation
Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases
Siitonen, H. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg306 · Cited by 196
Exomics and immunogenics
Champiat, S., Ferté, C., Lebel‐Binay, S., Eggermont, A. M. M., & Soria, J. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 195
Cancer in children and adolescents in Europe: Developments over 20 years and future challenges
Pritchard‐Jones, K., Kaatsch, P., Steliarova‐Foucher, E., Stiller, C. A., & Coebergh, J. W. W. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.006 · Cited by 195
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood
Vu, B. L., de Vathaire, F., Shamsaldin, A., Hawkins, M. M., Grimaud, E., Hardiman, C., Diallo, I., Vassal, G., Bessa, E., Campbell, S., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980729)77:3 · Cited by 193
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Gorlick, R. G., Anderson, P. M., Andrulis, I. L., Arndt, C., Beardsley, G. P., Bernstein, M. L., Bridge, J. A., Cheung, N. V., Dome, J. S., Ebb, D. H., et al. (2003) · PubMed · Cited by 193
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
Collins, M. L., Wilhelm, M., Conyers, R. K., Herschtal, A., Whelan, J. S., Bielack, S., Kager, L., Kühne, T., Sydes, M. R., Gelderblom, H. A. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8598 · Cited by 186
Self-citation
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S., & Wu, C. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0022 · Cited by 185
Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas
Scheel, C., Schaefer, K., Jauch, A. S., Keller, M., Wai, D., Brinkschmidt, C., van Valen, F., Boecker, W., Dockhorn‐Dworniczak, B., & Poremba, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204493 · Cited by 181
Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma
Bernthal, N. M., Federman, N. C., Eilber, F. R., Nelson, S. D., Eċkardt, J. J., Eilber, F. C., & Tap, W. D. (2012) · Cancer · doi:10.1002/cncr.27651 · Cited by 179
Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B
Karlsson, E. K., Sigurðsson, S., Ivansson, E. L., Thomas, R. J., Elvers, I., Wright, J. B., Howald, C., Tonomura, N., Perloski, M., Swofford, R., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-12-r132 · Cited by 178
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
Meyers, P. A., Healey, J. H., Chou, A. J., Wexler, L. H., Merola, P. R., Morris, C. D., LaQuaglia, M. P., Kellick, M. G., Abramson, S. J., & Gorlick, R. G. (2010) · Cancer · doi:10.1002/cncr.25744 · Cited by 177
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 Genes and Their Prognostic Implications in Osteosarcoma and Ewing Sarcoma
Tsuchiya, T., Sekine, K., Hinohara, S.-I., Namiki, T., Nobori, T., & Kaneko, Y. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00255-1 · Cited by 177
SHH mutation is associated with solitary median maxillary central incisor: A study of 13 patients and review of the literature
Nanni, L., Ming, J. E., Du, Y., Hall, R. K., Aldred, M. J., Bankier, A., & Muenke, M. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20010722)102:1 · Cited by 174
Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit, A. J., & Fidler, I. J. (1982) · PubMed · Cited by 171
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice
Ory, B., Heymann, M., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005) · Cancer · doi:10.1002/cncr.21530 · Cited by 169
The response of bone to mechanical loading and disuse: Fundamental principles and influences on osteoblast/osteocyte homeostasis
Skerry, T. M. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.02.028 · Cited by 166
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
Chen, W., Cooper, T. K., Zahnow, C. A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J. E., Gökgöz, N., Wunder, J. S., Andrulis, I. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.030 · Cited by 162
RecQ Helicases: Conserved Guardians of Genomic Integrity
Larsen, N. B., & Hickson, I. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5037-5_8 · Cited by 161
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
Weigel, B. J., Malempati, S., Reid, J. M., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M., Villaluna, D., Adamson, P. C., & Blaney, S. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24605 · Cited by 160
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157
Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site
Ulaner, G. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg034 · Cited by 154
Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 153
p53 and MDM2 alterations in osteosarcomas
Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8 · Cited by 147
Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma
Lau, C. C., Harris, C. P., Lu, X., Perlaky, L., Gogineni, S. K., Chintagumpala, M., Hicks, J. M., Johnson, M. E., Davino, N. A., Huvos, A. G., et al. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10291 · Cited by 146
Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
Jeys, L. M., Grimer, R. J., Carter, S. R., Tillman, R. M., & Abudu, A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9483-8 · Cited by 145
Genomic mechanisms and measurement of structural and numerical instability in cancer cells
Bayani, J., Selvarajah, S., Maire, G., Vukovic, B., Al-Romaih, K. I., Zieleńska, M., & Squire, J. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.006 · Cited by 144
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
Heymann, D., Ory, B., Blanchard, F., Heymann, M., Coipeau, P., Charrier, C., Couillaud, S., Thiery, J. P., Gouin, F., & Rédiní, F. (2005) · Bone · doi:10.1016/j.bone.2005.02.020 · Cited by 142
Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling
Sadiković, B., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Squire, J. A., & Zieleńska, M. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp117 · Cited by 141
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Gökgöz, N., Parkes, R. K., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 141
New concepts on the immune modulation mediated by mesenchymal stem cells
Bunnell, B. A., Betancourt, A. M., & Sullivan, D. E. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt34 · Cited by 139
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Navid, F., Santana, V. M., & Barfield, R. C. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054167 · Cited by 135
Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance
Chang, H. J., Yoo, B. C., Lim, S., Jeong, S., Kim, W. H., & Park, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1912 · Cited by 134
Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma
Rubin, E. M., Guo, Y., Tu, K., Xie, J., Zi, X., & Hoang, B. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0147 · Cited by 132
Gene amplifications in osteosarcoma—CGH microarray analysis
Atiye, J., Wolf, M., Kaur, S., Monni, O. M., Böhling, T., Kivioja, A., Tas, É., Serra, M., Tarkkanen, M., & Knuutila, S. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20120 · Cited by 130
Stature of young people with malignant bone tumors
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10437 · Cited by 129
High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25A
Vijayakumar, S., Liu, G., Rus, I. A., Yao, S., Chen, Y., Akiri, G., Grumolato, L., & Aaronson, S. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.010 · Cited by 128
Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma
Yang, J., Yang, D., Sun, Y. K., Sun, B., Wang, G., Trent, J. C., Araujo, D. M., Chen, K., & Zhang, W. (2011) · Cancer · doi:10.1002/cncr.26116 · Cited by 125
Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
Gökgöz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8 · Cited by 125
CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons
Guo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2 · Cited by 125
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma
Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD 2/ GD 3
Shibuya, H., Hamamura, K., Hotta, H., Matsumoto, Y., Nishida, Y., Hattori, H., Furukawa, K., Ueda, M., & Furukawa, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02344.x · Cited by 110
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Pignochino, Y., Dell’Aglio, C., Basiricò, M., Capozzi, F., Soster, M., Marchiò, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2293 · Cited by 107
Bone sarcomas in Paget disease: a study of 85 patients.
Smith, J. J., Botet, J. F., & Yeh, S. D. J. (1984) · Radiology · doi:10.1148/radiology.152.3.6235535 · Cited by 106
Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma
Kresse, S. H., Rydbeck, H., Skårn, M., Namløs, H. M., Barragan-Polania, A. H., Cleton-Jansen, A., Serra, M., Liestøl, K., Hogendoorn, P. C. W., Hovig, E. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048262 · Cited by 106
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
Freeman, S. S., Allen, S. W., Ganti, R., Wu, J., Ma, J., Su, X., Neale, G. A. M., Dome, J. S., Daw, N. C., & Khoury, J. D. (2008) · Cancer · doi:10.1002/cncr.23782 · Cited by 105
Genome-wide association studies in common cancers—what have we learnt?
Varghese, J. S., & Easton, D. F. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.03.012 · Cited by 105
Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13–15: A combined cytogenetic and comparative genomic hybridization study
Szymanska, J., Mandahl, N., Mertens, F., Tarkkanen, M., Karaharju, E. O., & Knuutila, S. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199605)16:1 · Cited by 102
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP
Watanabe, K., Okamoto, K., & Yonehara, S. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401507 · Cited by 102
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Molyneux, S. D., Grappa, M. A. D., Beristain, A. G., McKee, T. D., Wai, D., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42391 · Cited by 100
Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Karbach, J., Neumann, A., Brand, K., Wahle, C., Siegel, E., Maeurer, M. J., Ritter, E., Tsuji, T., Gnjatic, S., Old, L. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1116 · Cited by 98
Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program
Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., Wu, J., & Smith, M. A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22367 · Cited by 97
Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic
Cai, Y., Cai, T., & Chen, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24708 · Cited by 96
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
Kresse, S. H., Ohnstad, H. O., Paulsen, E. B., Bjerkehagen, B., Szuhai, K., Serra, M., Schaefer, K., Myklebost, O., & Meza‐Zepeda, L. A. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20675 · Cited by 96
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
Kuijjer, M. L., Peterse, E. F. P., van den Akker, B. E., Bruijn, I. H. B., Serra, M., Meza‐Zepeda, L. A., Myklebost, O., Hassan, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-245 · Cited by 95
Insulinlike Growth Factor I: A Potent Mitogen for Human Osteogenic Sarcoma
Pollak, M., Polychronakos, C., & Richard, M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.4.301 · Cited by 94
Physiology of Bone
Grabowski, P. (2009) · Endocrine development · doi:10.1159/000223687 · Cited by 89
Clinicopathologic Analysis of HER-2/neu Immunoexpression among Various Histologic Subtypes and Grades of Osteosarcoma
Kilpatrick, S. E., Geisinger, K. R., King, T. S., Sciarrotta, J., Ward, W. G., Gold, S., & Bos, G. D. (2001) · Modern Pathology · doi:10.1038/modpathol.3880474 · Cited by 88
Cell Cycle Regulator Gene CDC5L , a Potential Target for 6p12-p21 Amplicon in Osteosarcoma
Lu, X., Lu, Y., Zhao, Y., Jaeweon, K., Kang, J., Li, X., Ge, G., Meyer, R., Perlaky, L., Hicks, J. M., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2115 · Cited by 86
RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcoma
Lee, J. A., Jung, J. S., Kim, D. H., Lim, J. S., Kim, M. S., Kong, C., Song, W. S., Cho, W. H., Jeon, D., Lee, S., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22720 · Cited by 85
Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher, I., Birner, P., Trieb, K., Träxler, M., Lang, S., & Chott, A. (2003) · Modern Pathology · doi:10.1097/01.mp.0000043522.76788.0a · Cited by 81
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 80
Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group
Arndt, C. A. S., Koshkina, N., Inwards, C. Y., Hawkins, D. S., Krailo, M., Villaluna, D., Anderson, P. M., Goorin, A. M., Blakely, M. L., Bernstein, M. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0662 · Cited by 79
Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells
Mu, X., Isaac, C. E., Greco, N., Huard, J., & Weiss, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00143 · Cited by 77
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation
Kansara, M., Leong, H. S., Lin, D., Popkiss, S., Pang, P., Garsed, D. W., Walkley, C. R., Cullinane, C. M., Ellul, J., Haynes, N. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70559 · Cited by 77
Self-citation
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas
Entz‐Werlé, N., Stoetzel, C., Marec‐Bérard, P., Kalifa, C., Brugière, L., Pacquement, H., Schmitt, C., Tabone, M., Gentet, J., Quillet, R., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21068 · Cited by 75
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Himoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., et al. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0795-1 · Cited by 74
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
Yu, X., Wu, T. Y., Xiang, Y., Wei-ping, R. E. N., Zhou, Z. B., Sun, Y., & Zhang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1019-1 · Cited by 73
Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma
van Dartel, M., Cornelissen, P. W. A., Redeker, S., Tarkkanen, M., Knuutila, S., Hogendoorn, P. C. W., Westerveld, A., Gomes, I., Bras, J., & Hulsebos, T. J. M. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00627-1 · Cited by 70
Cancer‐germline gene expression in pediatric solid tumors using quantitative real‐time PCR
Jacobs, J. F. M., Brasseur, F., de Kaa, C. A. H., van de Rakt, M. W. M. M., Figdor, C. G., Adema, G. J., Hoogerbrugge, P. M., Coulie, P. G., & de Vries, I. J. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22118 · Cited by 69
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo
Hingorani, P., Zhang, W., Gorlick, R. G., & Kolb, E. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1657 · Cited by 68
Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma
Li, Y., Meng, G., & Guo, Q. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.03.013 · Cited by 67
Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
Worth, L. L., Jia, S.-F., Zhou, Z., Chen, L., & Kleinerman, E. S. (2000) · PubMed · Cited by 65
Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma
Koshkina, N. V., Khanna, C., Mendoza, A., Guan, H., DeLauter, L., & Kleinerman, E. S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0007 · Cited by 64
The Folate Receptor α Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate
Yang, R. R., Kolb, E. A., Qin, J., Chou, A. J., Sowers, R. S., Hoang, B. H., Healey, J. H., Huvos, A. G., Meyers, P. A., & Gorlick, R. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1343 · Cited by 64
Recurrent RECQL4 Imbalance and Increased Gene Expression Levels Are Associated with Structural Chromosomal Instability in Sporadic Osteosarcoma
Maire, G., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Zieleńska, M., & Squire, J. A. (2009) · Neoplasia · doi:10.1593/neo.81384 · Cited by 63
Inhibition of neutrophil oxidative burst and granule secretion by Wortmannin: Potential role of MAP kinase and renaturable kinases
Sue‐A‐Quan, A. K., Fialkow, L., Vlahos, C. J., Schelm, J. A., Grinstein, S., Butler, J. R., & Downey, G. P. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199707)172:1 · Cited by 63
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
Schwinger, W., Klass, V., Benesch, M., Lackner, H., Dornbusch, H. J., Sovinz, P., Moser, A., Schwantzer, G., & Urban, C. H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi226 · Cited by 63
Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
Spreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Stefano, A. D., Tintori, C., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-9873com · Cited by 63
C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells
MacEwen, E. G., Kutzke, J., Carew, J., Pastor, J., Schmidt, J. A., Tsan, R. Z., Thamm, D. H., & Radinsky, R. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1025404603315 · Cited by 62
Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma
Fletcher (2009) · International Journal of Oncology · doi:10.3892/ijo_00000390 · Cited by 62
Untitled work
(2001) · PubMed · Cited by 61
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
Moore, C. E., Eslin, D. E., Levy, A., Roberson, J. R., Giusti, V., & Sutphin, R. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22673 · Cited by 60
Cytotoxic T-lymphocyte Antigen-4 Polymorphisms and Susceptibility to Osteosarcoma
Liu, Y., He, Z., Feng, D., Shi, G., Gao, R., Wu, X., Song, W., & Yuan, W. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1269 · Cited by 60
Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone, S., Mutsuura, S., Ogawara, M., & Tsubura, E. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.2105 · Cited by 59
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Lockwood, W. W., Stack, D., Morris, T., Grehan, D., O’Keane, C., Stewart, G. L., Cumiskey, J., Lam, W. L., Squire, J. A., Thomas, D. M., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.020 · Cited by 59
Self-citation
COPS3 amplification and clinical outcome in osteosarcoma
Yan, T., Wunder, J. S., Gökgöz, N., Gill, M., Eskandarian, S., Parkes, R. K., Bull, S. B., Bell, R. S., & Andrulis, I. L. (2007) · Cancer · doi:10.1002/cncr.22595 · Cited by 59
Involvement of MET/TWIST/APC Combination or the Potential Role of Ossification Factors in Pediatric High-Grade Osteosarcoma Oncogenesis
Entz‐Werlé, N., Lavaux, T., Metzger, N., Stoetzel, C., Lasthaus, C., Marec‐Bérard, P., Kalita, C., Brugières, L., Pacquement, H., Schmitt, C., et al. (2007) · Neoplasia · doi:10.1593/neo.07367 · Cited by 59
Decitabine-Induced Demethylation of 5′ CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells
Al-Romaih, K. I., Sadiković, B., Yoshimoto, M., Wang, Y. Z., Zieleńska, M., & Squire, J. A. (2008) · Neoplasia · doi:10.1593/neo.08174 · Cited by 58
Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma
Hou, P., Ji, M., Yang, B., Chen, Z., Qiu, J., Shi, X., & Lu, Z. (2006) · Cancer · doi:10.1002/cncr.21762 · Cited by 57
Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma
Yang, J., Cogdell, D. E., Yang, D., Hu, L., Li, H., Zheng, H., Du, X., Pang, Y., Trent, J. C., Chen, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.018 · Cited by 57
Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma
Lin, C. H., Guo, Y., Ghaffar, S., McQueen, P., Pourmorady, J. S., Christ, A. B., Rooney, K., Ji, T., Eskander, R. H., Zi, X., et al. (2013) · Sarcoma · doi:10.1155/2013/147541 · Cited by 57
Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms.
Rathi, A., Virmani, A. K., Harada, K., Timmons, C. F., Miyajima, K., Hay, R. J., Mastrangelo, D., Maitra, A., Tomlinson, G. E., & Gazdar, A. F. (2003) · PubMed · Cited by 54
Aberrant Methylation of p14ARF Gene Correlates with Poor Survival in Osteosarcoma
Oh, J. H., Kim, H.-S., Kim, H., Kim, W. H., & Lee, S. H. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000188063.56091.69 · Cited by 52
Adjuvant Interferon Treatment of Human Osteosarcoma
Strander, H. A., Adamson, U. K. C., Aparisi, T., Broström, L., Cantell, K., Einhorn, S., Hall, K. E., Ingimarsson, S., Nilsonne, U., & Söderberg, G. (1979) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81332-0_7 · Cited by 52
Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma
KAWANO, M., ITONAGA, I., IWASAKI, T., & TSUMURA, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2224 · Cited by 51
The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
Sampson, E. R., Martin, B., Morris, A. E., Xie, C. L., Schwarz, E. M., O’Keefe, R. J., & Rosier, R. N. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.336 · Cited by 51
Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma
Lo, W. W., Wunder, J. S., Dickson, B. C., Campbell, V. T., McGovern, K., Alman, B. A., & Andrulis, I. L. (2013) · Cancer · doi:10.1002/cncr.28439 · Cited by 50
Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line
Capobianco, E., Mora, A., Sala, D. L., Roberti, A., Zaki, N., Badidi, E., Taranta, M., & Cinti, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095596 · Cited by 50
Pleiotropic effects of bisphosphonates on osteosarcoma
Ohba, T., Cates, J., Cole, H., Slosky, D., Haro, H., Ichikawa, J., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Bone · doi:10.1016/j.bone.2014.03.005 · Cited by 45
Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study
Strander, H. A., Bauer, H. C. F., Brosjö, O., Fernberg, J.-O., Andris Kreicbergs, A., Nilsonne, U., Silfverswärd, C., Signomklao, T., & Söderlund, V. (1995) · Acta Oncologica · doi:10.3109/02841869509127199 · Cited by 45
Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava, S. K., Wang, S., Tong, Y. A., Pirollo, K. F., & Chang, E. H. (1993) · PubMed · Cited by 45
The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases
Gordon, N. B., & Kleinerman, E. S. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_29 · Cited by 44
Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats
Chauvin, C., Philippeau, J.-M., Hémont, C., Hubert, F., Wittrant, Y., Lamoureux, F., Trinité, B., Heymann, D., Rédiní, F., & Josien, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0104 · Cited by 43
Targeting hedgehog‐GLI‐2 pathway in osteosarcoma
Yang, W., Liu, X., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2012) · Journal of Orthopaedic Research® · doi:10.1002/jor.22230 · Cited by 42
Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy
Tanaka, T., Yui, Y., Naka, N., Wakamatsu, T., Yoshioka, K., Araki, N., Yoshikawa, H., & Itoh, K. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9543-8 · Cited by 41
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma
Kelleher, F. C., Cain, J. E., Healy, J. M., Watkins, D. N., & Thomas, D. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.004 · Cited by 40
Self-citation
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédiní, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 40
Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma
Tsukahara, T., Kawaguchi, S., Torigoe, T., Kimura, S., Murase, M., Ichimiya, S., Wada, T., Kaya, M., Nagoya, S., Ishii, T., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00695.x · Cited by 40
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma
Yang, J., Zhao, L., Tian, W., Liao, Z., Zheng, H., Wang, G., & Chen, K. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-56 · Cited by 40
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
Tavanti, E., Sero, V., Vella, S., Fanelli, M., Michelacci, F., Landuzzi, L., Magagnoli, G., Versteeg, R., Picci, P., Hattinger, C. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.643 · Cited by 38
Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptides
Tsuda, N., Murayama, K., Ishida, H., Matsunaga, K., Komiya, S., Itoh, K., & Yamada, A. (2001) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(00)90031-7 · Cited by 36
Physiological and Oncogenic Aurora-A Pathway
Saeki, T., Ouchi, M., & Ouchi, T. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.758 · Cited by 36
Different expression of CD146 in human normal and osteosarcoma cell lines
Schiano, C., Grimaldi, V., Casamassimi, A., Infante, T., Esposito, A., Giovane, A., & Claudio Napoli, A. (2012) · Medical Oncology · doi:10.1007/s12032-012-0158-3 · Cited by 34
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling
Kolb, E. A., Gorlick, R. G., Keir, S. T., Maris, J. M., Lock, R. B., Carol, H., Kurmasheva, R. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23290 · Cited by 32
Inactivation of the RASSF1A in osteosarcoma
Lim, S., Yang, M., Park, J. H., Nojima, T., Hashimoto, H., Unni, K. K., & Park, Y.-K. (2003) · Oncology Reports · doi:10.3892/or.10.4.897 · Cited by 31
Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity
Zhou, Z., Lafleur, E. A., Koshkina, N. V., Worth, L. L., Lester, M. S., & Kleinerman, E. S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0092 · Cited by 31
153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients
Berger, M., Grignani, G., Giostra, A., Ferrari, S. M., Ferraresi, V., Tamburini, A., Cefalo, G., Carnevale‐Schianca, F., Vassallo, E., Picci, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr542 · Cited by 29
Paget disease of bone: Diagnosis and drug therapy
Seton, M. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12142 · Cited by 29
Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes
Mendoza, S., David, H., Gaylord, G. M., & Miller, C. W. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.08.035 · Cited by 28
Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells
Li, Y., Geng, P., Jiang, W., Wang, Y., Yao, J., Xu, L., Liu, J., Huang, L., Su, B., & Chen, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-1634-5 · Cited by 28
Osteoimmunology
Lorenzo, J., & Choi, Y. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00340.x · Cited by 28
Interferon-α enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis
Yuan, X.-W., Zhu, X., Huang, X.-F., Sheng, P.-Y., He, A.-S., Yang, Z.-B., Deng, R., Feng, G., & Liao, W.-M. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00662.x · Cited by 26
Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24
Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells
Li, Y., Huang, Y., Lv, Y., Meng, G., & Guo, Q. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.10.006 · Cited by 24
Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
Eilber, F. R., Townsend, C. M., & Morton, D. L. (1975) · PubMed · Cited by 23
Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis
Johal, S., Ralston, S., & Knight, C. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.2294 · Cited by 23
Werner's Syndrome
Rosén, R., Cimini, R., & Coblentz, D. (1970) · British Journal of Radiology · doi:10.1259/0007-1285-43-507-193 · Cited by 23
Radiation induced extraskeletal osteosarcoma
Logue, J. P., & Cairnduff, F. (1991) · British Journal of Radiology · doi:10.1259/0007-1285-64-758-171 · Cited by 22
Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion
Zhu, X. P., Liu, Z., Peng, A. F., Zhou, Y. F., LONG, X. H., LUO, Q. F., HUANG, S. H., & SHU, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1491 · Cited by 22
Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel‐Lindau tumor suppressor‐binding protein (CUL2 and VBP1) mutation and loss in renal‐cell carcinoma development
Clifford, S. C., Walsh, S., Hewson, K., Green, E., Brinke, A., Green, P. M., Gianelli, F., Eng, C., & Maher, E. R. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199909)26:1 · Cited by 22
Interferons and bone
Beresford, J. N., TAYLOR, G. T., & Triffitt, J. T. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19377.x · Cited by 21
Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma
Vettore, A. L., Sonaglio, de Carvalho, A. C., Toledo, S., Carvalho, de Camargo, B., Salinas-Souza, C., & Petrilli (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44918 · Cited by 21
Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
Ishida, H., Komiya, S., Inoue, Y., Yutani, S., Inoue, A., & Itoh, K. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.29 · Cited by 20
Osteosarcoma
Eilber, F. R., Townsend, C. M., & Morton, D. L. (1975) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197509000-00012 · Cited by 20
The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.
Kosmidis, P., Baxevanis, C. N., Tsavaris, N. B., Papanastasiou, M., Anastasopoulos, E., Bacoyiannis, C., Mylonakis, N., Karvounis, N., Bafaloukos, D. I., & Karabelis, A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1153 · Cited by 19
Antitumor effect of human leukocyte interferon on human osteosarcoma transplanted into nude mice
Masuda, S., Fukuma, H., & Beppu, Y. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90081-0 · Cited by 18
Interferons and osteosarcoma
Strander, H. A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.014 · Cited by 18
MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.
Bielack, S., Smeland, S., Whelan, J., Marina, N. M., Hook, J., Jovic, G., Krailo, M., Butterfaß‐Bahloul, T., Kühne, T., Eriksson, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba10504 · Cited by 18
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies
Liu, Y., Ma, Y., Sun, Z.-Z., Rui, Y., Yin, Q., da Song, S., Wei, X.-M., Liu, J., Liu, X., & Hu, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2165-9 · Cited by 17
Interferon-a enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis
Xiang-wei, Yuan, Xiaofeng, et al. (2007) · 中国药理学报：英文版 · Cited by 17
Novel physiological RECQL4 alternative transcript disclosed by molecular characterisation of Rothmund–Thomson Syndrome sibs with mild phenotype
Colombo, E. A., Fontana, L., Roversi, G., Negri, G., Castiglia, D., Paradisi, M., Zambruno, G., & Larizza, L. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.18 · Cited by 16
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Bielack, S., Smeland, S., Whelan, J. S., Marina, N. M., Hook, J., Jovic, G., Krailo, M., Butterfaß‐Bahloul, T., Kühne, T., Eriksson, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba10504 · Cited by 16

Flagged first, then by citations

1 of the 208 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Lussier, D. M. et al. 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) 162 (Society for Immunotherapy of Cancer, 2013).

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Update on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 494
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Comparative oncology: what dogs and other species can teach us about humans with cancer
Schiffman, J. D., & Breen, M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0231 · Cited by 445

See all 1,294

Authors: Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M.
Affiliations: The University of Melbourne (AU)
The University of Queensland (AU)
Garvan Institute of Medical Research (AU)
Corresponding author: Thomas, David M.
ORCID: Kansara, Maya
Teng, Michele W.
Smyth, Mark J.
Thomas, David M.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-10-16
Volume: 14
Issue: 11
Pages: 722-735
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3838
OpenAlex: W1980088710
Cited by: 1,294
References: 208
Citations by year: 2026: 66 · 2025: 130 · 2024: 134 · 2023: 155 · 2022: 161 · 2021: 173 · 2020: 152 · 2019: 86 · 2018: 66 · 2017: 74 · 2016: 65 · 2015: 29 · 2014: 2
FWCI: 9.69
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: osteosarcoma, bone biology, bone homeostasis, germline predisposition, cancer genomics, chromothripsis, kataegis, genomic instability, targeted therapy, mifamurtide, immune checkpoint inhibitors, adjuvant therapy, metastatic osteosarcoma, translational research
MeSH terms: Animals, Antineoplastic Agents, Bone Development, Humans, Osteosarcoma, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Translational biology of osteosarcoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks